Hybrid Peptide-Lipid Nanoparticles for Pulmonary Gene Therapy
This innovative hybrid nanoparticle platform successfully repurposes clinically validated lipid delivery technology for localized, high-expression pulmonary gene therapy. By reprogramming the protein corona to thrive in serum-poor environments, it unlocks a highly scalable, stable, and non-aggregating framework for delivering long-lasting DNA therapeutics directly to the lungs.
Background
Lipid nanoparticles (LNPs) are established vehicles for the systemic delivery of nucleic acid therapeutics, most notably seen in the rapid deployment of mRNA vaccines. However, treating chronic conditions, such as long-term lung diseases requiring sustained epithelial repair, demands DNA-based therapies, which offer prolonged gene expression and greater molecular stability than mRNA. Transitioning systemically successful LNPs to localized pulmonary delivery faces severe obstacles because the alveolar environment of the lung is naturally serum-poor. Traditional LNPs rely heavily on circulating blood proteins to form a “protein corona” that triggers cellular uptake; without these proteins in the lungs, conventional nanoparticles suffer from minimal cellular internalization, rapid lysosomal degradation, and poor gene expression.
Technology
University of Delaware Researchers have developed hybrid peptide-lipid nanoparticles (hpLNPs), a highly advanced coreshell delivery system specifically engineered for localized, highefficiency lung gene therapy. Manufactured via scalable microfluidic rapid mixing, the nanoparticle features a protective core of therapeutic DNA complexed with short, histone H3- derived peptides at an optimal amine-to-phosphate ratio, all encapsulated within a clinically validated lipid shell. Additionally platform overcomes the lung’s serum-deficient barrier by precoating the hpLNPs with a precise serum fraction prior to administration, the peptide additives successfully reprogram the nanoparticle’s protein corona. This modification drives specific interactions with serum exosome components, circumventing natural cellular resistance to achieve up to a 17-fold increase in transgene expression compared to standard LNPs, all while maintaining an ideal particle size and a DNA encapsulation efficiency exceeding 90%. This innovative hybrid nanoparticle platform successfully repurposes clinically validated lipid delivery technology for localized, high-expression pulmonary gene therapy.
Benefits
-
Higher Gene Expression: Overcomes traditional pulmonary delivery barriers to deliver up to a 17-fold increase in lung transgene expression compared to standard formulations.
-
Reprogrammed Protein Corona: Uses unique peptide-mediated conditioning to leverage exosome-guided cellular uptake, bypassing the limitations of the lung’s serum-poor alveolar space.
-
Superior Encapsulation & Quality: Consistently maintains a premium DNA encapsulation efficiency above 90% while preserving strict colloidal stability and preventing particle aggregation.
-
Prolonged Therapeutic Stability: Enables the use of durable DNA-based therapeutics rather than transient mRNA, ensuring long-lasting gene expression for chronic disease management.
-
Scalable & Translatable Framework: Fully compatible with established microfluidic manufacturing and clinically approved lipid architectures, ensuring a rapid path to clinical translation.
Applications
- Pulmonary gene therapy delivery
Additional info
Hybrid peptide-lipid nanoparticles feature a core-shell architecture synthesized via microfluidic rapid mixing. The core contains DNA complexed with histone H3-derived peptides at an N/P ratio of 0.9, encased by an ALC-0315, ALC-0159, cholesterol, and DSPC lipid shell (47.5:1.8:40.7:10 molar ratio). Exhibiting 60–150 nm hydrodynamic sizes, >90% DNA encapsulation, and a pKa of 6.60–6.65, they utilize serum pre-coating to reprogram their protein corona with exosome components, enhancing pulmonary cellular uptake and transfection.